Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3β and a receptor-independent anti-oxidative action

Journal of Neurochemistry

Volumn 104, Issue 4, 2008, Pages 946-956

  Yu, Yang ^a   Wang, Jing Ru ^a   Sun, Pei Hua ^a   Guo, Yang ^a   Zhang, Zhang Jin ^b   Jin, Guo Zhang ^a   Zhen, Xuechu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

3 methyl 6 chloro 7,8 hydroxy 1 (3 methylphenyl) 2, 3,4,5 tetrahydro 1H 3 benzazepine; Apoptosis; Dopamine receptor; Glycogen synthase kinase 3 ; Neuroprotection; Nitric oxide

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; GLUTATHIONE PEROXIDASE; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROGEN PEROXIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NITRIC OXIDE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CELL; BRAIN CORTEX; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; LIPID PEROXIDATION; NEUROPROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ANTIOXIDANTS; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOGEN SYNTHASE KINASE 3; NEUROPROTECTIVE AGENTS; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1;

RATTUS;

EID: 38549147516     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.05062.x     Document Type: Article

References (37)

1. Agnati L. F., Leo G., Vergoni A. V., Martinez E., Hockemeyer J., Lluis C., Franco R., Fuxe K. Ferre S. (2004) Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. Brain Res. Bull. 64, 155 164.
2. Andringa G., Stoof J. C. Cools A. R. (1999) Sub-chronic administration of the dopamine D(1) antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology (Berl.) 146, 328 334.
3. Arnt J., Hyttel J. Sanchez C. (1992) Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur. J. Pharmacol. 213, 259 267.
4. Banker G. A. Cowan W. M. (1977) Rat hippocampal neurons in dispersed cell culture. Brain Res. 126, 397 425.
5. Beal M. F. (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38, 357 366.
6. Clifford J. J., Tighe O., Croke D. T., Kinsella A., Sibley D. R., Drago J. Waddington J. L. (1999) Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase. Neuroscience 93, 1483 1489.
7. Cools A. R., Lubbers L., van Oosten R. V. Andringa G. (2002) SKF 83959 is an antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus accumbens: a key to its antiparkinsonian effect in animals? Neuropharmacology 42, 237 245.
8. Cotter T. G. Martin S. J. (1996) Techniques in Apoptosis. Portland Press Ltd, London.
9. Cross C. E., Halliwell B., Borish E. T., Pryor W. A., Ames B. N., Saul R. L., McCord J. M. Harman D. (1987) Oxygen radicals and human disease. Ann. Intern. Med. 107, 526 545.
10. Dash P. R., Whitley G. S., Ayling L. J., Johnstone A. P. Cartwright J. E. (2005) Trophoblast apoptosis is inhibited by hepatocyte growth factor through the Akt and beta-catenin mediated up-regulation of inducible nitric oxide synthase. Cell. Signal. 17, 571 580.
11. Deveney A. M. Waddington J. L. (1995) Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase. Br. J. Pharmacol. 116, 2120 2126.
12. Estevez A. G., Spear N., Thompson J. A., Cornwell T. L., Radi R., Barbeito L. Beckman J. S. (1998) Nitric oxide-dependent production of cGMP supports the survival of rat embryonic motor neurons cultured with brain-derived neurotrophic factor. J. Neurosci. 18, 3708 3714.
13. Farinelli S. E., Park D. S. Greene L. A. (1996) Nitric oxide delays the death of trophic factor-deprived PC12 cells and sympathetic neurons by a cGMP-mediated mechanism. J. Neurosci. 16, 2325 2334.
14. Gnanalingham K. K., Hunter A. J., Jenner P. Marsden C. D. (1995a) The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology (Berl.) 117, 287 297.
15. Gnanalingham K. K., Erol D. D., Hunter A. J., Smith L. A., Jenner P. Marsden C. D. (1995b) Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology (Berl.) 117, 275 286.
16. Green L. C., Wagner D. A., Glogowski J., Skipper P. L., Wishnok J. S. Tannenbaum S. R. (1982) Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 126, 131 138.
17. Hall A. G. (1999) Review: the role of glutathione in the regulation of apoptosis. Eur. J. Clin. Invest. 29, 238 245.
18. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97, 1634 1658.
19. Jin L. Q., Goswami S., Cai G., Zhen X. Friedman E. (2003) SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. J. Neurochem. 85, 378 386.
20. Kim Y. M., Bombeck C. A. Billiar T. R. (1999) Nitric oxide as a bifunctional regulator of apoptosis. Circ. Res. 84, 253 256.
21. Mihara M. Uchiyama M. (1978) Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 86, 271 278.
22. Nutt J. G., Carter J. H., Lea E. S. Woodward W. R. (1997) Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov. Disord. 12, 285 292.
23. Obeso J. A., Rodriguez-Oroz M., Marin C., Alonso F., Zamarbide I., Lanciego J. L. Rodriguez-Diaz M. (2004) The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62, S17 S30.
24. Olanow C. W. Obeso J. A. (2000) Preventing levodopa-induced dyskinesias. Ann. Neurol. 47, S167 S176 discussion S176 S168.
25. Panchalingam S. Undie A. S. (2001) SKF83959 exhibits biochemical agonism by stimulating [(35)S]GTP gamma S binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacology 40, 826 837.
26. Rashid A. J., So C. H., Kong M. M., Furtak T., El-Ghundi M., Cheng R., O'Dowd B. F. George S. R. (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl Acad. Sci. USA 104, 654 659.
27. Shin S. Y., Chin B. R., Lee Y. H. Kim J. H. (2006) Involvement of glycogen synthase kinase-3beta in hydrogen peroxide-induced suppression of Tcf/Lef-dependent transcriptional activity. Cell. Signal. 18, 601 607.
28. Song L., De Sarno P. Jope R. S. (2002) Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J. Biol. Chem. 277, 44701 44708.
29. Thannickal V. J. Fanburg B. L. (2000) Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 279, L1005 L1028.
30. Valko M., Morris H. Cronin M. T. (2005) Metals, toxicity and oxidative stress. Curr. Med. Chem. 12, 1161 1208.
31. Waddington J. L., O'Tuathaigh C., O'Sullivan G., Tomiyama K., Koshikawa N. Croke D. T. (2005) Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology (Berl.) 181, 611 638.
32. Whittemore E. R., Loo D. T., Watt J. A. Cotman C. W. (1995) A detailed analysis of hydrogen peroxide-induced cell death in primary neuronal culture. Neuroscience 67, 921 932.
33. Wirtshafter D. Osborn C. V. (2005) The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats. Eur. J. Pharmacol. 528, 88 94.
34. Zhang J., Dawson V. L., Dawson T. M. Snyder S. H. (1994) Nitric oxide activation of poly (ADP-ribose) synthetase in neurotoxicity. Science 263, 687 689.
35. Zhang H., Ma L. Q., Wang F., Chen J. G. Zhen X. C. (2007) Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neuropharmacology 53, 125 133.
36. Zhen X., Goswami S., Abdali S. A., Gil M., Bakshi K. Friedman E. (2004) Regulation of cyclin-dependent kinase 5 and calcium/calmodulin-dependent protein kinase II by phosphatidylinositol-linked dopamine receptor in rat brain. Mol. Pharmacol. 66, 1500 1507.
37. Zhen X., Goswami S. Friedman E. (2005) The role of the phosphatidyinositol-linked D1 dopamine receptor in the pharmacology of SKF83959. Pharmacol. Biochem. Behav. 80, 597 601.